Payment overview · 2025
General Payments
$786.75
56 reported records · 15 companies
Healthcare provider profile · identity verified
Thomas C Chapman, DO
Allopathic & Osteopathic Physicians|Family Medicine · KANSAS CITY, MO · NPI 1932167897
Verified facts
What the public records show
CMS Open Payments records show Thomas C Chapman, DO received $786.75 in general payments during 2025 across 56 reported records.
ABBVIE INC. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Mounjaro, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.28 | 22.7% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.89 | 18.3% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.55 | 15.6% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $106.71 | 13.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $55.97 | 7.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.25 | 4.0% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $22.87 | 2.9% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.73 | 2.8% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $21.22 | 2.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.82 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.36 | 2.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.92 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.29 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.90 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.99 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $786.75 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $157.02 | 18 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $106.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.18 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.04 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $87.04 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $79.42 | 8 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.71 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.71 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.71 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $7.55 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 53 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 112 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
53 | 53 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 459 | 131 |
| Lisinopril | Lisinopril | 386 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 88 |
| Gabapentin | Gabapentin | 261 | 77 |
| Metformin Hcl Er | Metformin Hcl | 189 | 70 |
| Omeprazole | Omeprazole | 189 | 52 |
| Alprazolam | Alprazolam | 187 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 55 |
| Carvedilol | Carvedilol | 175 | 52 |
| Simvastatin | Simvastatin | 168 | 48 |
| Jardiance | Empagliflozin | 156 | 41 |
| Eliquis | Apixaban | 150 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 38 |
| Losartan Potassium | Losartan Potassium | 149 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 44 |
| Metformin Hcl | Metformin Hcl | 141 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 34 |
| Celecoxib | Celecoxib | 120 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 34 |
| Meloxicam | Meloxicam | 115 | 50 |
| Tramadol Hcl | Tramadol Hcl | 113 | 43 |
| Mounjaro | Tirzepatide | 112 | 22 |
| Allopurinol | Allopurinol | 107 | 29 |
| Trazodone Hcl | Trazodone Hcl | 107 | 31 |
| Potassium Chloride | Potassium Chloride | 106 | 34 |
| Bupropion Xl | Bupropion Hcl | 100 | 23 |
| Montelukast Sodium | Montelukast Sodium | 98 | 30 |
| Furosemide | Furosemide | 94 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 45 |
| Ezetimibe | Ezetimibe | 84 | 23 |
| Fenofibrate | Fenofibrate | 81 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 22 |
| Clonazepam | Clonazepam | 77 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 23 |
| Famotidine | Famotidine | 68 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 28 |
| Alendronate Sodium | Alendronate Sodium | 65 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Glimepiride | Glimepiride | 62 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 14 |
| Irbesartan | Irbesartan | 54 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 53 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 21 |
| Farxiga | Dapagliflozin Propanediol | 53 | 14 |
| Valsartan | Valsartan | 52 | 13 |
| Sertraline Hcl | Sertraline Hcl | 51 | 18 |
| Topiramate | Topiramate | 49 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 14 |
| Ozempic | Semaglutide | 48 | 15 |
| Spironolactone | Spironolactone | 48 | 12 |
| Azithromycin | Azithromycin | 47 | 41 |
| Ondansetron Odt | Ondansetron | 47 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 14 |
| Methylprednisolone | Methylprednisolone | 42 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 33 |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | 16 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 39 | 12 |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 38 | 17 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 25 |
| Estradiol | Estradiol | 35 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | 11 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Xtampza Er | Oxycodone Myristate | 25 | suppressed |
| Felodipine Er | Felodipine | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Prednisone | Prednisone | 18 | 12 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 11 | 11 |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $786.75 · 56 records | ABBVIE INC. | AREXVY, CREON, CRYSVITA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IBSRELA, INSPIRE, KISUNLA, LINZESS, Leqembi, MOUNJARO, OTEZLA, Omnipod, Paradise Ultrasound Renal Denervation System, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Yorvipath, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error